Abstract

The prevalence of human immunodeficiency virus is high among female sex workers (FSWs) in Indonesia, underscoring the need for integrated prevention strategies supported by strong government policies. This study aimed to investigate FSWs' willingness to participate in a pre-exposure prophylaxis (PrEP) program. This qualitative study employed semi-structured interviews with 20 participants residing in Pangkal Pinang City, Indonesia (4 stakeholders and 16 FSWs), recruited through purposive sampling. Data were collected from July to September 2024. This non-probability sampling method was adopted due to the focus on specific study objectives and a targeted population. The analysis of the interviews revealed three theme clusters comprising eight themes. The identified clusters were government policy, knowledge of effectiveness and willingness to follow PrEP, and readiness for side effects and long-term compliance. Improving health services in areas where FSWs are concentrated is crucial for facilitating easier access with lower transportation costs. Furthermore, supporting the privacy of FSWs is crucial, and the cost of health screening before PrEP initiation should be waived to eliminate financial barriers and encourage participation in the PrEP program.

References

1. Joint United Nations Programme on HIV/AIDS. HIV Prevention 2020 Road Map: Accelerating HIV Prevention to Reduce New Infections by 75%. Geneva: Joint United Nations Programme on HIV/AIDS; 2020.

2. Moyo E, Murewanhema G, Moyo P, et al. The use of oral human immunodeficiency virus pre-exposure prophylaxis in pregnant and lactating women in sub-Saharan Africa: Considerations, barriers, and recommendations. Glob Health J. 2024; 8 (2): 41–45. DOI: 10.1016/j.glohj.2024.04.002.

3. Direktorat Jenderal Pencegahan dan Penanggulangan Penyakit. Survei Terpadu Biologis dan Perilaku (STBP) Populasi Kunci Tahun 2023. Jakarta: Kementerian Kesehatan Republik Indonesia; 2024.

4. Kiggundu R, Soh QR, Tieosapjaroen W, et al. Restarting pre-exposure prophylaxis (PrEP) for HIV: A systematic review and meta-analysis. EClinicalMedicine. 2024; 72: 102647. DOI: 10.1016/j.eclinm.2024.102647.

5. McAllister ER, Wilson JE, Bojang M, et al. Implementing a workflow process for human immunodeficiency virus pre-exposure prophylaxis (PrEP): A quality improvement initiative. J Nurs Pract. 2024; 20 (8): 105116. DOI: 10.1016/j.nurpra.2024.105116.

6. Sullivan PS, Sanchez TH, Zlotorzynska M, et al. National trends in HIV pre‐exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017. J Int AIDS Soc. 2020; 23 (3): e25461. DOI: 10.1002/jia2.25461.

7. Godfrey-Faussett P, Frescura L, Abdool Karim Q, et al. HIV prevention for the next decade: appropriate, person-centred, prioritised, effective, combination prevention. PLoS Med. 2022; 19 (9): e1004102. DOI: 10.1371/journal.pmed.1004102.

8. Fernández Piñeiro N, Ayerdi Aguirrebengoa O, Orviz García E, et al. Pre-exposure prophylaxis program in the Community of Madrid: Two years of experience. Enferm Infecc Microbiol Clin (Engl Ed). 2025; 43 (3): 133–138. DOI: 10.1016/j.eimce.2024.06.001.

9. Rousseau E, Katz AWK, O’Rourke S, et al. Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS One. 2021; 16 (10): e0258542. DOI: 10.1371/journal.pone.0258542.

10. Schaefer R, Schmidt HMA, Ravasi G, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: A global summary and forecasting study. Lancet HIV. 2021; 8 (8): e502–e510. DOI: 10.1016/s2352-3018(21)00127-2.

11. Tsuchiya K, Hayashi Y, Ryu S, et al. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence. J Infect Chemother. 2024; 30 (9): 876–880. DOI: 10.1016/j.jiac.2024.02.028.

12. Smith DK, Sullivan PS, Cadwell B, et al. Evidence of an association of increases in pre-exposure prophylaxis coverage with decreases in human immunodeficiency virus diagnosis rates in the United States, 2012–2016. Clin Infect Dis. 2020; 71 (12): 3144–3151. DOI: 10.1093/cid/ciz1229.

13. Kurniawan DE, Wijaya D. Intention toward pre-exposure prophylaxis use among female sex workers from rural area: A cross-sectional study in Jember, Indonesia. Malays J Med Health Sci. 2024; 20 (5): 86-92. DOI: 10.47836/mjmhs.20.5.12.

14. Pratiwi NPP, Ani LS, Sutarsa IN. Acceptance strategy of HIV pre-exposure prophylaxis for female sex workers in Badung, Bali, Indonesia. Public Health Prevent Med Arch. 2024; 12 (1): 66–77. DOI: 10.53638/phpma.2024.v12.i1.p06.

15. Feliu A, Barrera B, Drury A, et al. Perceptions towards the adoption of multi-risk factors cancer prevention educational tool among European Union citizens: A multi-country qualitative study protocol. Int J Quali Method. 2024; 23: 16094069241256276. DOI: 10.1177/16094069241256276.

16. Fauk NK, Sukmawati AS, Wardojo SSI, et al. The intention of men who have sex with men to participate in voluntary counseling and HIV testing and access free condoms in Indonesia. Am J Men Health. 2018; 12 (5): 1175–1184. DOI: 10.1177/1557988318779737.

17. Kementrian Kesehatan Republik Indonesia. Guidelines for oral pre-expose prophylaxis (PREP) program for people at high-risk of HIV infection in Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia; 2023.

18. Eakle R, Bourne A, Mbogua J, et al. Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa. J Int AIDS Soc. 2018; 21 (2): e25081. DOI: 10.1002/jia2.25081.

19. Augustus EH, George C, Rocke KD. Pre-exposure prophylaxis in Latin America and the Caribbean—the Barbados experience. J Health Care Poor Underserved. 2023; 34 (1): 58–73. DOI: 10.1353/hpu.2023.0005.

20. Galárraga O, Wilson-Barthes M, Chivardi C, et al. Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: A randomized pilot trial among male sex workers in Mexico. Eur J Health Econ. 2025; 26 (2): 299–311. DOI: 10.1007/s10198-024-01705-y.

21. Kelley CF, Kahle E, Siegler A, et al. Applying a PrEP continuum of care for men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2015; 61 (10): 1590–1597. DOI: 10.1093/cid/civ664.

22. Gilles M, Tetart M, Huleux T, et al. HIV pre-exposure prophylaxis (PrEP) knowledge among general practitioners in 2020: A French survey. Infect Dis Now. 2023; 53 (3): 104649. DOI: 10.1016/j.idnow.2023.104649

23. Mwanri L, Fauk NK, Kustanti CY, et al. HIV susceptibility among clients of female sex workers in Indonesia: A qualitative inquiry. Sex Health. 2018; 15 (3): 246–253. DOI: 10.1071/sh17137.

24. Poteat T, Malik M, van der Merwe LLA, et al. PrEP awareness and engagement among transgender women in South Africa: A cross-sectional, mixed methods study. Lancet HIV. 2020; 7 (12): e825–e834. DOI: 10.1016/s2352-3018(20)30119-3.

25. Koppe U, Marcus U, Albrecht S, et al. Factors associated with the informal use of HIV pre‐exposure prophylaxis in Germany: A cross‐sectional study. J Int AIDS Soc. 2019; 22 (10): e25395. DOI: 10.1002/jia2.25395.

26. Ahaus P, Schmidt AJ, Skaletz-Rorowski A, et al. Changes in the user profiles of HIV pre-exposure prophylaxis (PrEP) before and after PrEP reimbursement. J Infect Public Health. 2022; 15 (9): 955–960. DOI: 10.1016/j.jiph.2022.07.012.

27. Bunting SR, Feinstein BA, Hazra A, et al. Knowledge of HIV and HIV pre-exposure prophylaxis among medical and pharmacy students: A national, multi-site, cross-sectional study. Prevent Med Rep. 2021; 24: 101590. DOI: 10.1016/j.pmedr.2021.101590.

28. Elliott T, Sanders EJ, Doherty M, et al. Challenges of HIV diagnosis and management in the context of pre‐exposure prophylaxis (PrEP), post‐exposure prophylaxis (PEP), test and start and acute HIV infection: A scoping review. J Int AIDS Soc. 2019; 22 (12): e25419. DOI: 10.1002/jia2.25419.

29. Bleasdale J, Wilson K, Aidoo-Frimpong G, et al. Prescribing HIV pre-exposure prophylaxis: A qualitative analysis of health care provider training needs. J HIV/AIDS Soc Sci. 2020; 19 (1): 107–123. DOI: 10.1080/15381501.2020.1712291.

30. Graham SM, Okall DO, Mehta SD, et al. Challenges with PrEP uptake and adherence among gay, bisexual, and other men who have sex with men in Kisumu, Kenya. AIDS Behav. 2023; 27 (4): 1234–1247. DOI: 10.1007/s10461-022-03860-w.

31. Zimmermann HML, Eekman SW, Achterbergh RCA, et al. Motives for choosing, switching and stopping daily or event‐driven pre‐exposure prophylaxis – a qualitative analysis. J Int AIDS Soc. 2019; 22 (10): e25389. DOI: 10.1002/jia2.25389.

32. Gaspar M, Tan DHS, Lachowsky N, et al. HIV pre-exposure prophylaxis (PrEP) should be free across Canada to those meeting evidence-based guidelines. Can J Human Sex. 2022 ;31 (3): 309–313. DOI: 10.3138/cjhs.2022-0004.

Download

Share

COinS